AKT1 and colorectal cancer: In this regard, luteolin was already reported to alter antioxidant activity, modulate the MAPK and p-IGF-1R/PI3K/AKT/mTOR signaling pathways, and induce mitochondrial dysfunction in GBM, colorectal cancers and other malignancies [54,55,56,57,58].